NETs marker AUCs according to time of inclusion and revascularisation by PCI or not
| Inclusion time after symptom onset | PCI | |||||
| ≤2 days | >2 days | P value | No | Yes | P value | |
| H3Cit | ||||||
| Placebo | 9.8 (6.8, 15.4) | 9.9 (5.7, 22.6) | 0.586 | 10.8 (5.4, 19.9) | 9.3 (6.2, 17.9) | 0.624 |
| Tocilizumab | 21.7 (13.5, 40.9) | 19.2 (9.7, 40.0) | 0.465 | 23.2 (11.8, 46.9) | 20.2 (10.2, 38.1) | 0.556 |
| dsDNA | ||||||
| Placebo | 1823 (1721, 1986) | 1787 (1664, 1952) | 0.641 | 1764 (1601, 1967) | 1829 (1735, 1977) | 0.243 |
| Tocilizumab | 1857 (1783, 1994) | 1761 (1622, 1935) | 0.079 | 1939 (1609, 2200) | 1798 (1694, 1920) | 0.235 |
| MPO–DNA | ||||||
| Placebo | 0.911 (0.651, 1.681) | 0.893 (0.665, 1.451) | 0.701 | 1.354 (0.846, 1.655) | 0.777 (0.644, 1.459) | 0.068 |
| Tocilizumab | 1.357 (0.622, 3.046) | 0.946 (0.666, 1.419) | 0.270 | 1.035 (0.620, 2.902) | 1.068 (0.673, 1.937) | 0.834 |
Numbers are given as medians (25, 75 percentiles).
AUC, area under the curve; dsDNA, double-stranded DNA; H3Cit, citrullinated histone 3; MPO–DNA, myeloperoxidase–DNA; NETs, neutrophil extracellular traps; PCI, percutaneous coronary intervention.